NeuroBo Pharmaceuticals, Inc. Annual Operating Income (Loss) in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
NeuroBo Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2014 to 2023.
  • NeuroBo Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$6.26M, a 60.8% decline year-over-year.
  • NeuroBo Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$28.9M, a 39.9% decline year-over-year.
  • NeuroBo Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$15.9M, a 19.1% increase from 2022.
  • NeuroBo Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$19.6M, a 28.3% decline from 2021.
  • NeuroBo Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$15.3M, a 48.5% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$15.9M +$3.74M +19.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-28
2022 -$19.6M -$4.33M -28.3% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 -$15.3M +$14.4M +48.5% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-30
2020 -$29.7M -$9.54M -47.3% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
2019 -$20.2M -$4.69M -30.3% Jan 1, 2019 Dec 31, 2019 10-K 2021-04-15
2018 -$15.5M +$17.6M +53.2% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-30
2017 -$33.1M -$18.4M -125% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-18
2016 -$14.7M -$6.62M -82% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-18
2015 -$8.08M -$7.81M -2936% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-20
2014 -$266K Jan 1, 2014 Dec 31, 2014 10-K 2017-03-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.